Gene therapy digest - 2021

Gene therapy digest - 2021

XyloCor advances its lead gene therapy candidate for refractory angina to Phase 2

XC001 (AAV gene therapy; Phase 2) – XyloCor Therapeutics

  • Phase 1 dose-escalation part of Phase 1/2 clinical trial (EXACT) for XC001 (encoberminogene rezmadenovec) was completed
  • XC001 delivers the gene for VEGF in targeted myocardial cells, stimulating the creation of new blood vessels via angiogenesis
  • It employs a proprietary multi-isoform VEGF expression cassette that has been optimized to maximize expression of VEGF
  • XC001 is being investigated as an one-time treatment for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularization procedures
  • In May 2017, FDA granted fast track designation for XC001 (For full story click here)

XyloCor’s funding extension moves its regenerative heart disease gene therapy further in the clinics

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Commentary:

  • XyloCor $22.6 million Series A extension three years after its first fundraiser helped in the completion and expansion of their clinical trials
  • Planned studies:
    • Phase 2 study for XC001 as adjunctive therapy to coronary artery bypass grafting in 2H21
    • Trial in heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention

– Dr. Kowndinya, CI Scientists

Home